Trevor M Penning1, Daniel Tamae. 1. Department of Systems Pharmacology and Translational Therapeutics, Center of Excellence in Environmental Toxicology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Abstract
PURPOSE OF REVIEW: Androgen deprivation therapy is a cornerstone in the treatment of advanced prostate cancer and has extended the lives of countless patients. Unfortunately, many of these patients eventually succumb to metastatic castration-resistant prostate cancer (mCRPC). The efficacy of abiraterone acetate (AA, Zytiga) and enzalutamide (Enza, Xtandi) in the mCRPC setting prove that these tumors remain androgen-driven. We review recent studies that have shown that intratumoral androgen biosynthesis plays a significant role in the ever-evolving mCRPC tumor and we discuss the therapeutic implications of these findings. RECENT FINDINGS: A novel abiraterone metabolite, 17-(pyridin-3-yl)androsta-4,16-dien-3-one (D4A), possesses robust antitumor activity in rodent models via the inhibition of androgen biosynthetic enzymes and antagonism of the androgen receptor. The TMPRSS2 : ERG fusion drives aldo-keto reductase 1C3 (AKR1C3) expression and activity to facilitate androgen biosynthesis and activate the androgen receptor in prostate cancer. Intracrine androgen formation and AKR1C3 expression and activity have been found to confer resistance to enzalutamide. SUMMARY: These studies highlight the significant role that intratumoral androgen biosynthesis plays in the mCRPC tumor. The therapeutic implications include the inhibition of AKR1C3 in tumors that become resistant to current drugs such as abiraterone acetate or Enza and the potential administration of D4A as an mCRPC therapeutic.
PURPOSE OF REVIEW: Androgen deprivation therapy is a cornerstone in the treatment of advanced prostate cancer and has extended the lives of countless patients. Unfortunately, many of these patients eventually succumb to metastatic castration-resistant prostate cancer (mCRPC). The efficacy of abiraterone acetate (AA, Zytiga) and enzalutamide (Enza, Xtandi) in the mCRPC setting prove that these tumors remain androgen-driven. We review recent studies that have shown that intratumoral androgen biosynthesis plays a significant role in the ever-evolving mCRPC tumor and we discuss the therapeutic implications of these findings. RECENT FINDINGS: A novel abiraterone metabolite, 17-(pyridin-3-yl)androsta-4,16-dien-3-one (D4A), possesses robust antitumor activity in rodent models via the inhibition of androgen biosynthetic enzymes and antagonism of the androgen receptor. The TMPRSS2 : ERG fusion drives aldo-keto reductase 1C3 (AKR1C3) expression and activity to facilitate androgen biosynthesis and activate the androgen receptor in prostate cancer. Intracrine androgen formation and AKR1C3 expression and activity have been found to confer resistance to enzalutamide. SUMMARY: These studies highlight the significant role that intratumoral androgen biosynthesis plays in the mCRPC tumor. The therapeutic implications include the inhibition of AKR1C3 in tumors that become resistant to current drugs such as abiraterone acetate or Enza and the potential administration of D4A as an mCRPC therapeutic.
Authors: Muralimohan Yepuru; Zhongzhi Wu; Anand Kulkarni; Feng Yin; Christina M Barrett; Juhyun Kim; Mitchell S Steiner; Duane D Miller; James T Dalton; Ramesh Narayanan Journal: Clin Cancer Res Date: 2013-08-30 Impact factor: 12.531
Authors: Daniel Tamae; Elahe Mostaghel; Bruce Montgomery; Peter S Nelson; Steven P Balk; Philip W Kantoff; Mary-Ellen Taplin; Trevor M Penning Journal: Chem Biol Interact Date: 2014-12-13 Impact factor: 5.192
Authors: Matias Knuuttila; Emrah Yatkin; Jenny Kallio; Saija Savolainen; Teemu D Laajala; Tero Aittokallio; Riikka Oksala; Merja Häkkinen; Pekka Keski-Rahkonen; Seppo Auriola; Matti Poutanen; Sari Mäkelä Journal: Am J Pathol Date: 2014-06-17 Impact factor: 4.307
Authors: Karim Fizazi; Christophe Massard; Petri Bono; Robert Jones; Vesa Kataja; Nicholas James; Jorge A Garcia; Andrew Protheroe; Teuvo L Tammela; Tony Elliott; Leena Mattila; John Aspegren; Annamari Vuorela; Peter Langmuir; Mika Mustonen Journal: Lancet Oncol Date: 2014-06-25 Impact factor: 41.316
Authors: Malcolm D Mason; Wendy R Parulekar; Matthew R Sydes; Michael Brundage; Peter Kirkbride; Mary Gospodarowicz; Richard Cowan; Edmund C Kostashuk; John Anderson; Gregory Swanson; Mahesh K B Parmar; Charles Hayter; Gordana Jovic; Andrea Hiltz; John Hetherington; Jinka Sathya; James B P Barber; Michael McKenzie; Salah El-Sharkawi; Luis Souhami; P D John Hardman; Bingshu E Chen; Padraig Warde Journal: J Clin Oncol Date: 2015-02-17 Impact factor: 44.544
Authors: Lucas J Brand; Margaret E Olson; Preethi Ravindranathan; Hong Guo; Aaron M Kempema; Timothy E Andrews; Xiaoli Chen; Ganesh V Raj; Daniel A Harki; Scott M Dehm Journal: Oncotarget Date: 2015-02-28